JP2008502698A - アルブテロール、及びカルシウム活性化カリウムチャネルオープナーの使用方法。 - Google Patents

アルブテロール、及びカルシウム活性化カリウムチャネルオープナーの使用方法。 Download PDF

Info

Publication number
JP2008502698A
JP2008502698A JP2007516693A JP2007516693A JP2008502698A JP 2008502698 A JP2008502698 A JP 2008502698A JP 2007516693 A JP2007516693 A JP 2007516693A JP 2007516693 A JP2007516693 A JP 2007516693A JP 2008502698 A JP2008502698 A JP 2008502698A
Authority
JP
Japan
Prior art keywords
albuterol
potassium channel
pharmaceutically acceptable
dosage form
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007516693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008502698A5 (enExample
Inventor
ジェイ． バルベリチ ティモシイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of JP2008502698A publication Critical patent/JP2008502698A/ja
Publication of JP2008502698A5 publication Critical patent/JP2008502698A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2007516693A 2004-06-14 2005-06-14 アルブテロール、及びカルシウム活性化カリウムチャネルオープナーの使用方法。 Abandoned JP2008502698A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57882704P 2004-06-14 2004-06-14
US59902704P 2004-08-06 2004-08-06
US60729004P 2004-09-07 2004-09-07
PCT/US2005/021171 WO2005123071A1 (en) 2004-06-14 2005-06-14 Methods of using albuterol and calcium activated potassium channel openers

Publications (2)

Publication Number Publication Date
JP2008502698A true JP2008502698A (ja) 2008-01-31
JP2008502698A5 JP2008502698A5 (enExample) 2008-07-31

Family

ID=35509445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007516693A Abandoned JP2008502698A (ja) 2004-06-14 2005-06-14 アルブテロール、及びカルシウム活性化カリウムチャネルオープナーの使用方法。

Country Status (6)

Country Link
US (1) US20090035224A1 (enExample)
EP (1) EP1773325A4 (enExample)
JP (1) JP2008502698A (enExample)
AU (1) AU2005254096A1 (enExample)
CA (1) CA2570386A1 (enExample)
WO (1) WO2005123071A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013056925A (ja) * 2012-11-21 2013-03-28 Rottapharm Spa アンドラスト／グルココルチコイドの併用
JP2014097977A (ja) * 2012-10-17 2014-05-29 Maruzen Pharmaceut Co Ltd Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311771T3 (es) * 2004-08-19 2009-02-16 Rottapharm S.P.A. Derivados en n-fenilbenzamida como farmacos para el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc).
US20100015061A1 (en) * 2006-01-06 2010-01-21 Boehringer Ingeheim International GmnH Pharmaceutical Compositions Based on Anticholinergics and Andolast
WO2008014814A1 (en) * 2006-07-31 2008-02-07 Rottapharm S.P.A. Combination andolast/glucocorticoids
CN112535668B (zh) * 2020-10-29 2023-08-18 苏州君宁新药开发中心有限公司 一种左旋硫酸沙丁胺醇颗粒剂及其用途
CN113476428B (zh) * 2021-01-28 2022-03-29 朗天药业(湖北)有限公司 一种吸入用硫酸沙丁胺醇溶液及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2085468T3 (es) * 1990-01-05 1996-06-01 Sepracor Inc Albuterol r(-) opticamente puro para tratar el asma.
US5200422A (en) * 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
US5637470A (en) * 1994-05-13 1997-06-10 Merck & Co., Inc. Screening array using cells expressing recombinant α and β subunits of the mammalian large-conductance (maxi-K) potassium channel
DE69722610T2 (de) * 1997-08-08 2004-04-29 Rotta Research Laboratorium S.P.A., Monza Neue Inhalationspräparate enthaltend CR 2039 (Andolast)
CA2341488A1 (en) * 1998-08-26 2000-03-09 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
US6656461B1 (en) * 2000-02-29 2003-12-02 The Trustees Of Columbia University In The City Of New York Therapeutic treatment of chronic obstructive pulmonary disease
US7713964B2 (en) * 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014097977A (ja) * 2012-10-17 2014-05-29 Maruzen Pharmaceut Co Ltd Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物
JP2013056925A (ja) * 2012-11-21 2013-03-28 Rottapharm Spa アンドラスト／グルココルチコイドの併用

Also Published As

Publication number Publication date
WO2005123071A1 (en) 2005-12-29
AU2005254096A1 (en) 2005-12-29
EP1773325A1 (en) 2007-04-18
EP1773325A4 (en) 2007-11-07
US20090035224A1 (en) 2009-02-05
CA2570386A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
JP7621220B2 (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
US8501816B2 (en) Antitussive compositions comprising memantine
ES2762806T3 (es) Tratamiento utilizando estabilizadores de mastocitos para trastornos sistémicos
ES2356093T3 (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol.
US20040235807A1 (en) Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
CN102573823B (zh) 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
BR102016010170A2 (pt) Stabilized pharmaceutical composition of prolonged release containing antidepressives
JP5941258B2 (ja) 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
JPWO2002096405A1 (ja) 医薬配合剤
JP2008502699A (ja) 肺疾患治療方法、及びそのための組成物
US20090035224A1 (en) Methods of Using Albuterol and Calcium Activated Potassium Channel Openers
US20250099402A1 (en) Compositions of aspirin and ketamine
US20050244498A1 (en) Modified-release compositions of at least one form of venlafaxine
JP6061924B2 (ja) 口腔内分散性製剤
KR20080013927A (ko) 벤라팍스의 하나 이상 형태의 개질 방출 조성물
US20080014261A1 (en) Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
WO2006030221A1 (en) Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent
CA2570448A1 (en) Methods and compositions for the treatment of pulmonary diseases
US20240082176A1 (en) Dropropizine in combination with ambroxol in the dosage form of syrup and tablets
TR201611685A1 (tr) Oral farmasöti̇k terki̇pler
TR201612324A1 (tr) Solunum Yolu Hastalıklarında Kullanılan Farmasötik Terkipler
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
AU2011236040A1 (en) (R,R)-Formoterol in combination with other pharmacological agents
TR201611687A1 (tr) Oral farmasöti̇k terki̇pler
CN101180039A (zh) 至少一种形式的文拉法辛的缓释组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080612

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20100406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100406